Tab Modafil (modafinil)

# Tab Modafil (modafinil) ## Overview Modafinil is a wakefulness-promoting agent. Its exact mechanism of action is not fully understood, but it is believed to affect dopamine, norepinephrine, and histamine pathways in the brain. ## Primary Indications * **Narcolepsy:** To improve wakefulness. * **Obstructive Sleep Apnea (OSA):** As an adjunct to continuous positive airway pressure (CPAP) or other treatments to reduce excessive daytime sleepiness (EDS) in patients with OSA. * **Shift Work Sleep Disorder (SWSD):** To reduce EDS in patients with SWSD who work rotating shifts. ## Adult Dosing * **Narcolepsy:** 200 mg orally once daily, taken in the morning. Doses up to 400 mg/day have been used, divided into two doses (morning and noon). * **OSA:** 200 mg orally once daily, taken in the morning. * **SWSD:** 200 mg orally once daily, taken approximately 1 hour before the start of the work shift. ## Pediatric Dosing Dosing for modafinil in pediatric patients is not well-established. Use in pediatric populations should be based on expert consensus or specific clinical trial data, which is limited. Caution is advised. ## Dose Adjustments * **Hepatic Impairment:** Reduce the dose by 50% in patients with severe hepatic impairment. * **Renal Impairment:** No specific dose adjustment is recommended for mild to moderate renal impairment. For severe renal impairment, caution is advised, and a dose reduction may be considered. ## Contraindications * Known hypersensitivity to modafinil or any of its ingredients. * Use in patients with severe hepatic impairment (dose reduction recommended). ## Adverse Effects Common adverse effects include headache, nausea, nervousness, insomnia, diarrhea, dizziness, and rash. Serious skin reactions (e.g., Stevens-Johnson syndrome) have been reported rarely and require immediate discontinuation. Psychiatric effects such as anxiety, depression, and hallucinations have also occurred. ## Key Drug Interactions * **CYP3A4 Substrates:** Modafinil is a weak inducer of CYP3A4. It may decrease the plasma concentrations of drugs metabolized by this enzyme, potentially reducing their efficacy (e.g., hormonal contraceptives, cyclosporine, midazolam). Consider alternative contraception or increased doses of the affected drug. * **CYP2C19 Inhibitors/Inducers:** Modafinil may inhibit CYP2C19, increasing the exposure to drugs metabolized by this enzyme (e.g., phenytoin, omeprazole). * **Tricyclic Antidepressants and MAOIs:** Use with caution due to potential for additive effects on monoamines. * **Stimulants:** Use with caution due to potential for additive stimulant effects and increased risk of cardiovascular events. ## Monitoring * Monitor for signs of serious skin reactions. * Assess for psychiatric symptoms (anxiety, depression, hallucinations). * Evaluate efficacy in improving wakefulness. * Monitor for potential drug interactions, especially with CYP3A4 substrates and CYP2C19 substrates. ## Clinical Pearls * Modafinil should be taken in the morning to avoid disruption of nighttime sleep. * It is not a cure for sleep disorders but rather a treatment to manage symptoms of EDS. * For SWSD, it should be used only in patients with a diagnosis of SWSD and should not be used to manage simple sleep logging or other non-valid circadian rhythm disorders. * Women using hormonal contraceptives should use an alternative or additional non-hormonal method of contraception during treatment with modafinil and for at least one month after discontinuation. *** **Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive prescribing information or clinical judgment. Always consult the most current official prescribing information and relevant literature for complete details, including specific warnings, precautions, and contraindications, before making any treatment decisions.